HLA proteins act as an alarm system for detection of cancerous and infected cells by presenting a foreign or aberrant peptide to T cells. Using its proprietary soluble HLA-expressing cell lines, Pure MHC is able to simulate the disease state and identify the HLA peptide complexes that distinguish cancerous or infected cells.
Pure MHC’s epitope discovery technology is the only technology that can identify peptide epitopes that are both: 1) unique to or upregulated in the affected state, and 2) compared to and validated as ligands presented by HLA molecules on primary tissues of interest.
The Pure MHC Epitope Discovery Process:
- identifies high quality targets
- utilizes the capabilities to study all 120 Class I HLA alleles, as well as Class II, non-classical HLA molecules
- allows access to intracellular targets
- validates, rather than predicts, that target is “actually” expressed
- is agnostic to previously reported targets
- overcomes heterogeneity in tumors and pathogen strains
Epitope Discovery Competitor Analysis
|Class I allelesNon-classical Class I alleles
Class II alleles
|Yes (121 currently available)Yes (HLA-E, HLA-F, HLA-G, CD1c, CD1d)
Yes (37 currently available)
|Maximum Ligands Identified
|MHC isolation||Soluble HLA||Detergent Cell Lysate|
|MHC restriction||Known, allele specific||Predicted by typing, mix of multiple alleles|
|Source||Any transfectable cell line or primary tissue||HumanMouse|
|Host Cell Species||Any species available||HumanMouse|
Non-human Primates (Mamu, Mafa, Gogo, Patr)
Any other species with MHC (Fla, Cfa, Gga, etc.)
|Antigen Delivery||ExogenousEndogenous (Pathogen Infection)||Exogenous|
|Peptide Origin||Purified ProteinVaccine
Pathogens (up to BSL III)
Small molecule drugs
Endogenous Self Peptides
* Typical results for soluble Class I HLA from cell lines; may depend on allele. Note: Publications available for reference.
Want to learn more?
For more information Contact Us.